395 related articles for article (PubMed ID: 28256432)
1. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
Tuchman SA; Moore JO; DeCastro CD; Li Z; Sellars E; Kang Y; Long G; Gasparetto CG
J Geriatr Oncol; 2017 May; 8(3):165-169. PubMed ID: 28256432
[TBL] [Abstract][Full Text] [Related]
2. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Wilson JN; Jenner MW; Cook G; Kaiser MF; Drayson MT; Owen RG; Russell NH; Gregory WM; Morgan GJ;
Lancet Haematol; 2019 Dec; 6(12):e616-e629. PubMed ID: 31624047
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients.
Li F; Yao FS; Zhu XJ; Gu WY; Wang XH; Chen B; Huang DP; Ding JH; Wu TQ; Zhu Y; Zhao Q; Tang YM; Song P; Zhou XG; An ZM; Guo X; Wang XL; Zhong L; Xie XB; Zhai YP
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2343-2355. PubMed ID: 31280348
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T; Hagihara M; Sahara N; Tamai Y; Ishii R; Tamaki S; Wake A; Tajika K; Sakai R; Kobayashi T; Hua J; Inoue M; Aisa Y; Fujisawa S; Miyazaki K; Irie S; Tanaka E; Higashihara M
Ann Hematol; 2021 Nov; 100(11):2745-2754. PubMed ID: 34333665
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Einsele H; Engelhardt M; Tapprich C; Müller J; Liebisch P; Langer C; Kropff M; Mügge LO; Jung W; Wolf HH; Metzner B; Hart C; Gramatzki M; Hertenstein B; Pfreundschuh M; Rösler W; Fischer T; Maschmeyer G; Kanz L; Hess G; Jäger E; Bentz M; Dürk HA; Salwender H; Hebart H; Straka C; Knop S
Br J Haematol; 2017 Nov; 179(4):586-597. PubMed ID: 28961309
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gunawardena S; Lutska Y; Qi K; Ukropec J; Qi M; Lin TS; Rifkin RM
Br J Haematol; 2019 May; 185(3):492-502. PubMed ID: 30828799
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
Kropff M; Vogel M; Bisping G; Schlag R; Weide R; Knauf W; Fiechtner H; Kojouharoff G; Kremers S; Berdel WE
Ann Hematol; 2017 Nov; 96(11):1857-1866. PubMed ID: 28905189
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
10. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
Nishihori T; Baz R; Shain K; Kim J; Ochoa-Bayona JL; Yue B; Sullivan D; Dalton W; Alsina M
Eur J Haematol; 2015 Nov; 95(5):426-35. PubMed ID: 25600676
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients.
de Waal EG; de Munck L; Hoogendoorn M; Woolthuis G; van der Velden A; Tromp Y; Vellenga E; Hovenga S
Br J Haematol; 2015 Dec; 171(5):720-5. PubMed ID: 26358087
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Muranushi H; Kanda J; Kobayashi M; Maeda T; Kitano T; Tsuji M; Ueda Y; Ishikawa T; Nohgawa M; Watanabe M; Imada K; Moriguchi T; Itoh M; Ohno H; Yonezawa A; Hirata H; Arima N; Asagoe K; Anzai N; Nagata K; Yasuno S; Kuwabara Y; Kitao H; Kim I; Kawagishi K; Ueshima K; Tominari S; Nakayama T; Yamashita K; Takaori-Kondo A
Hematology; 2022 Dec; 27(1):239-248. PubMed ID: 35152852
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis.
Suzuki K; Tsukada N; Nishimura N; Nagata Y; Okazuka K; Mishima Y; Yokoyama M; Nishiwaki K; Ishida T; Yano S; Terui Y; Suzuki K
Int J Hematol; 2020 Jan; 111(1):103-111. PubMed ID: 31673952
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell EK; Laubach JP; Yee AJ; Chen T; Huff CA; Basile FG; Wade PM; Paba-Prada CE; Ghobrial IM; Schlossman RL; Burke JN; Harrington CC; Lively KJ; Lyons HF; Munshi NC; Anderson KC; Trippa L; Richardson PG; Raje NS
Br J Haematol; 2018 Jul; 182(2):222-230. PubMed ID: 29740809
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cyclophosphamide-thalidomide-dexamethasone to bortezomib-cyclophosphamide-dexamethasone as induction therapy for multiple myeloma patients in Brazil.
Vigolo S; Zuckermann J; Bittencourt RI; Silla L; Pilger DA
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):135-142. PubMed ID: 28636891
[TBL] [Abstract][Full Text] [Related]
16. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Uttervall K; Borg Bruchfeld J; Gran C; Wålinder G; Månsson R; Lund J; Gahrton G; Alici E; Nahi H
Eur J Haematol; 2019 Sep; 103(3):247-254. PubMed ID: 31231833
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Ibata S; Sato T; Kuroda H; Nagamachi Y; Iyama S; Fujimi A; Kamihara Y; Konuma Y; Yoshida M; Tatekoshi A; Hashimoto A; Horiguchi H; Ono K; Murase K; Takada K; Miyanishi K; Kobune M; Hirayama Y; Kato J
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1041-1049. PubMed ID: 27738809
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
